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SUMMARY 
Pregnant Sprague-Dawley-Holtzman rats were laparoto-
mized on either the nineteenth or the twentieth days of ges­
tation (ether anesthesia). The fetuses were injected in utero 
with growth hormone, insulin, or thyroxine. Saline-injected 
fetuses served as controls. Following the injections, the 
maternal abdominal wall was sutured and the skin closed with 
wound clips. Twenty-four hours later, the fetuses were re­
moved and weighed. The livers were weighed and then assayed 
for glycogen. Thyroxine administration was found to have in­
creased hepatic glycogen deposition. 
These results prompted a study of the effect of hor­
mone treatment on two enzymes active in the fetus which may 
serve as control points in fetal metabolism. These enzymes 
were UDPG-glycogen glueosyltransferase and hexokinase. Glu-
cokinase was assayed concurrently with hexokinase. 
Surgery similar to that described above was performed 
on pregnant Sprague-Dawley-Holtzman rats with the following 
changes. The pregnant females were laparotomized and the fe­
tuses injected on either the fifteenth or the nineteenth days 
of gestation. Fetuses received treatment identical to fetuses 
in the glycogen experiment. However, each liver was assayed 
for independent(I) and dependent (D) UDPG-glycogen glucosyl 
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transferase or for hexokinase and glucokinase. 
The results of this experiment demonstrated that the 
effect of thyroxine administration on glycogen deposition late 
in gestation is not mediated through an increase in the acti­
vity of either the I or the D form of UDPG-glycogen glucosyl-
transferase. Instead, the effect may be achieved through in­
creased availability of glucose for incorporation into glyco­
gen or through alteration of cellular metabolites which may 
stimulate glycogenesis, 
Glucokinase activity was found to be absent on the six­
teenth and the twentieth days of gestation in controls as well 
as in hormonally treated livers. 
Hexokinase activity was increased significantly at day 
16 and day 20 by the injection of growth hormone. This in­
crease may be mediated through a protein anabolic effect by 
this hormone. Insulin appeared to increase the activity of 
hexokinase at day 2 0 , but an analysis of variance did not show 
a significant difference between the mean of the treatment 
activities and that of the control activities. A ranking test 
did show a significant difference between the activity means 
within mothers, indicating that there was indeed a bias. The 
treatment of more animals may show a significant effect by in­
sulin on hexokinase activity. 
CHAPTER I 
INTRODUCTION 
The purpose of this research was to demonstrate the 
effects of insulin, growth hormone, and thyroxine on hepatic 
uridine diphosphoglucose (UDPG)-glycogen glucosyltransferase, 
hexokinase, and glucokinase in the fetus, UDPG-glycogen glu­
cosyltransf erase plays a key role in the deposition of glyco­
gen in the liver late in development. At birth the glycogen 
will be used to maintain a sufficient blood glucose level un­
til the newborn's metabolism achieves the transition between 
prenatal glucose metabolism and postnatal lipid metabolism (1), 
The fetus derives its serum glucose primarily from the mother 
by means of the placenta and not via endogenous production. 
This glucose probably serves as a prime energy source for 
metabolism and as the main source for glycogenesis. The high 
activity of hexokinase before birth suggests a high capacity 
for phosphorylating glucose (2), Although liver glucokinase 
reputedly does not appear until weaning, it was assayed con­
currently for the possible effects of prenatal hormone admin­
istration. 
It has been found that key enzyme changes in mammalian 
liver are associated with specific developmental changes ( 3 ) . 
Of particular importance are those changes occurring in the 
late fetal period (the sixteenth to the twentieth day of ges­
tation) of development which prepare the fetus for the metabolic 
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changes at birth. The late fetal changes seen in the enzyme 
profiles of the liver occur concurrently with or just after 
the onset of pituitary, thyroid, adrenal cortical, and pan­
creatic p-cell function. The concurrence of the two events 
suggests that the rise in fetal hormone production may serve 
as a trigger for enzymic differentiation. Fetal injection 
of representative hormones appearing late in gestation may 
provide some insight into enzymic differentiation. Logical 
choices of hormones for fetal administration would be insulin, 
growth hormone, and thyroxine. 
An increase in the activity of a certain enzyme fol­
lowing the administration of a certain hormone late in ges­
tation (day 19) could give an indication of the function of 
the hormone in the fetus. Early enzymic differentiation re­
sulting from hormone administration prior to the normal ap­
pearance of an enzyme (day 15) could indicate the hormone as 
a trigger, an important link in the initial control of devel­
opment of a particular enzyme. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
Enzymic differentiation has become the topic of in­
tensive research in recent years. The term enzymic differ­
entiation is used to indicate the process whereby organs ac­
quire their characteristic enzyme patterns (4). Much inter­
est has been shown in this process in liver tissue because 
of the importance of its enzymes in survival following birth. 
A survey of the data available on rat liver indicates discon­
tinuous changes in the enzyme profile. Specific developmental 
stages are associated with extensive enzyme changes. Because 
enzyme changes tend to cluster in time, the specific enzymes 
are grouped according to the developmental stage in which they 
first appear. 
The three stages of development which are associated 
with intense changes in enzyme activity are (a) the late fe­
tal period, the sixteenth to the twentieth day of gestation5 
(b) the early neonatal period, the first day of birth5 and 
(c) the late suckling period, the third weefc of postnatal 
life (4). These changes in enzymic differentiation occur 
along with changes in the hormone profile; the late fetal 
period of development is associated with the initiation of 
endocrine secretion of several glands. Studies with labeled 
iodine uptake in the fetal rat thyroid indicate that the fetus 
is secreting thyroid hormone by the seventeenth day of gesta­
tion ( 5 ) . Experiments by Jost have demonstrated evidence of 
thyroxine secretion before measurable iodine uptake, thereby 
suggesting that thyroid function may actually begin slightly 
before the seventeenth day ( 6 ) , The adrenal gland develops 
in the rat between the twelfth and sixteenth day of gestation 
and is capable of corticosterone secretion on the fourteenth 
day ( 7 ) . Adrenal secretion comes under trophic control on 
the sixteenth day of gestation with the beginning of pituitary 
function. Pituitary secretion does not seem to be necessary 
for early development of either the thyroid or the adrenal 
gland but does exert trophic control over the secretions of 
these glands late in gestation ( 1 ) . The 3-cells of the pan­
creas are functional on the twelfth day as demonstrated by 
the onset of insulin secretion at that time ( 8 ) . 
Jost was one of the first to experiment with the ef­
fects of fetal endocrine function on biochemical differenti­
ation. His work has shown that hypophysectomy by decapita­
tion of the fetal rabbit does influence biochemical differ­
entiation (9). The liver does not produce and accumulate ap­
preciable amounts of glycogen unless glucocorticoids and a 
pituitary extract are administered. Jacquot and Kretchmer 
later demonstrated that the enzymes required for fetal rat 
liver glycogen formation (expecially UDPG-glycogen glucosyl-
transferase) fail to reach their customary high activities 
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after hypophysectomy unless glucocorticoids are adminis­
tered (10). Such endocrine ablation studies have been help­
ful in indicating possible roles of endocrine products on 
differentiationj however, evaluation of the results of such 
experiments is limited. Endocrine ablation, especially when 
performed by fetal decapitation, may deprive the fetus of 
a host of hormones or substrates rather than of a single 
one. The technique of hormone administration to an intact 
fetus has recently become the method of choice. While endo­
crine ablation experiments can only indicate which factors 
are necessary for enzymic differentiation, hormone administra­
tion experiments may indicate the order of importance of 
those factors and which factor serves as the trigger for 
differentiation. On the whole, hormone administration in 
utero seems to be a more positive approach while inflicting 
minimum injury and trauma to the fetus. 
In 196l Jost postulated that the late phase of rapid 
glycogen accumulation in fetal liver depends on adrenal and 
pituitary hormones (11). In 1964, Grillo et al, demonstrated 
that initial glycogen deposition corresponds with the earli­
est detection of UDPG-glycogen glueosyltransferase and with 
the onset of insulin secretion on the twelfth day of gestation 
(12). Monder and Coufalik returned to the earlier experi­
ments and found that Cortisol stimulated the synthesis of 
glycogen in fetal rat liver explants (13)1 the applicability 
of this experiment to the in vivo situation may be questionable 
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because substrate availability and intracellular environment 
in an in vitro incubation may vary substantially from that 
found in vivo. 
Greengard and Dewey found that administration of glu­
cocorticoid to the intact fetus prior to the normal increase 
in glycogen accumulation induced early deposition of glyco­
gen and thus may serve as a trigger (14). Recent experi­
ments by Parsa have shown a positive correlation between 
levels of glucosyltransferase and the development of rough 
and smooth endoplasmic reticulum in chick liver (15). The 
absence of insulin in explants prevents the development of 
endoplasmic reticulum, the induction of glucosyltransferase, 
and the deposition of glycogen. 
Less is known about the differentiation of hexokinase. 
Burch et al. found that hexokinase activity decreases from 
the fifteenth day of gestation until the twenty-first day af­
ter birth ( 1 6 ) (See Appendix B ) . Schaub et al. substantiated 
this conclusion ( 3 ) . No evidence of the effects of prenatal 
hormone administration on hexokinase was found in the survey 
of the literature. 
Glucokinase differentiation has been the object of much 
research. Walker reported that fetal guinea-pig liver con­
tains a glucokinase which has a low K m (17). No such enzyme 
has been reported in the fetal rat. Rat liver glucokinase 
does not appear until the time of weaning (sixteen to twenty 
days following birth) (18-22). The normal appearance of 
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glucokinase is triggered by insulin and glucose ( 2 3 ) . Jam-
dar and Greengard have prematurely induced the appearance 
of glucokinase on the ninth day following birth by repeated 
injections of glucose and hydrocortisone ( 2 1 ) . 
Greengard and Dewey have performed several experiments 
involving the effects of prenatal hormone administration on 
other enzymes of the late fetal and early neonatal clusters. 
They have found that thyroxine elevates considerably the 
levels of glucose-6-phosphatase and NADPHicytochrome c oxi-
doreductase when administered between the eighteenth and 
twenty-second days of gestation (24), When administered in 
the same way, glucagon has a similar effect on glucose -6 -
phosphatase and can prematurely evoke the synthesis of tyro­
sine aminotransferase and serine dehydratase, enzymes of 
the neonatal cluster ( 2 5 ) . These results have led Greengard 
to postulate that the accumulation of new enzymes and gains 
or losses in the concentrations of enzymes already present 
late in gestation may be associated with the onset of thyroid 
function. Similarly, the enzymatic changes seen at birth may 
be associated with the onset of glucagon secretion as a re­
sult of neonatal hypoglycemia (4), While her theories are 
plausible, the experimental data might be questioned on the 
basis of the dosages of thyroxine administered ( 3 p.g« per fe­
tus). The thyroxine dosage used with her fetuses has been 
shown to produce euthyroidism in thyroidectomized adult rats 
weighing 2 0 0 to 3 0 0 grams ( 2 6-28). Although a physiological 
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dose of thyroxine in a fetus has not been defined, one must 
be cautious when evaluating results of administration of what 
may be a pharmacological dose, a dose resulting in the levels 
of thyroxine being substantially higher than the normal endog­
enous levels, 
Greengard*s theories of the mechanisms of enzyme de­
velopment are based on the development of competence (a state 
of responsiveness) of liver cells for enzyme synthesis. For 
instance, tyrosine aminotransferase, an enzyme of the neonatal 
cluster, can be evoked one or two days before birth by the 
administration of glucagon; however, administration of this 
hormone three or more days before birth cannot evoke the 
aminotransferase (4). Further experimentation demonstrated 
that cyclic adenosine monophosphate (cyclic AMP) can evoke 
tyrosine aminotransferase synthesis on the eighteenth or 
nineteenth day of gestation. Thus, the competence of the 
liver to produce cyclic AMP on the nineteenth day of gesta­
tion in response to glucagon may be the key to the early ap­
pearance of the aminotransferase, 
Greengard has also done some work on the relationship 
of gene expression to enzymic differentiation. Unfortunate­
ly, the Jacob-Monod model of enzyme regulation in bacteria 
does not apply in higher organisms since there is no evidence 
of the existence of regulatory genes, operons, or repressors. 
She postulates that the active gene for synthesis of a speci­
fic enzyme is a necessary but not the only condition for 
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enzyme synthesis. Unless the messenger ribonucleic acid 
(mRNA) is present, the enzyme is not produced; however, the 
mRNA may be present hours or days before the production of 
the enzyme. Thus, the absence of the enzyme indicates only 
that at least one of the steps required for its synthesis is 
inoperative, but it does not indicate the identity of the in­
operative step. Conversely, v/hen an enzyme appears, all 
necessary reactions are operative, but it is not apparent 
which step has suddenly become operative. The final pre­
requisite might have been the formation of the mRNA, but it 
is also possible that transcription was operative earlier and 
that the appearance of some cofactor was the missing factor 
necessary for completion of the protein chain. Many research­
ers are attempting to implicate endocrine secretions as fac­
tors which may control protein synthesis at some point or may 
provide the cofactors necessary for the completion of protein 
chains. 
The specific hormones administered in this study have 
been shown to affect the enzyme profile of the adult liver 
and thus may have a prenatal influence on enzymic differen­
tiation. Insulin has been found to increase the activities 
of adult UDPG-glycogen glucosyltransferase, hexokinase, and 
glucokinase ( 2 9 » 3 0 ) , Furthermore, insulin has been shown to 
be necessary for normal development of glucosyltransferase in 
fetal chick liver explants (15). Grillo has shown a correla­
tion between formation of this enzyme and the initiation of 
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fetal insulin secretion (12). Insulin has also been shown to 
trigger early development of neonatal glucokinase (23). 
Small doses of thyroxine potentiate the effects of in­
sulin on glycogen synthesis and glucose utilization (29). 
Thyroxine is also known to increase adult hexokinase activity 
(31). Specific effects of growth hormone on the enzymes test­
ed here are not documented in the literature; however, growth 
hormone is known to increase the release of insulin and to 
increase the levels of glucose-6-phosphate in the adult. Such 
evidence in the adult justifies the study of these hormones 
in the fetus, though it does not guarantee the same results. 
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CHAPTER III 
MATERIALS AND METHODS 
Surgical Procedures and Experimental Designs 
Glycogen Experiment 
Virgin Sprague-Dawley-Holtzman rats ranging in weight 
from 2 5 0 to 275 grams were bred and considered pregnant when 
spermatozoa were found in the vaginal tract; the day of sper­
matozoa detection was designated as gestational day zero. On 
the nineteenth or the twentieth day of gestation,, an abdominal 
incision was made on the female (ether anesthesia) to expose 
the uterus. The fetuses were injected with 10 u.1. of either 
thyroxine (T^) (0.01 u,g.), bovine insulin (0.004 units), 
ovine growth hormone (GH) (0.01 units), or saline ( 0 . 9 $ sodium 
chloride). The dosages of hormones were determined by adjust­
ing (to average fetal weight) those dosages considered to be 
physiological in the adult. All hormones were dissolved in 
saline. The saline-injected fetuses served as controls. In­
jections were intraperitoneal. 
Fetuses within each horn of a given mother were alter­
nately injected with saline or with a hormone. Care was taken 
to assure that each litter contained at least one fetus in 
each of the three hormone treatment groups. A control was 
obtained for each position in the horn within a given mother. 
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Following the injections, the abdominal muscle was su­
tured and the skin closed with wound clips. Twenty-four hours 
following the injection, the mother was anesthetized with 
ether and the fetuses were removed and weighed. The liver was 
then removed from each fetus, weighed, and assayed for gly­
cogen. 
Ether anesthesia is known to mobilize glycogen. How­
ever, this mobilization is a function of the initial concen­
tration of glycogen. Therefore the effect would be to mini­
mize the differences between the mean of the glycogen level 
in a treatment group and that in a control group. Thus, the 
use of ether anesthesia could obscure a true treatment effect. 
However, the presence of a significant difference between the 
mean of a treatment group and the mean of the control group 
would be indicative of a distinct effect by the hormone. A 
similar effect of minimizing the differences between groups 
may be seen on those enzymes assayed for in the following ex­
periment. However, little is known of the effect of ether on 
enzyme activities. 
Enzyme Experiment 
The surgical procedure used in the experiments involv­
ing the effect of hormone administration on enzyme activity 
was similar to the procedure discussed above with the follow­
ing changes. Pregnant Sprague-Dawley-Holtzman rats were 
laparotomized on either the fifteenth or the nineteenth day 
of gestation. Fetuses injected on the fifteenth day were 
13 
treated with fiveu . 1 , of ( 0 . 0 0 5 |ig.)» insulin ( 0 . 0 0 2 units), 
GH ( 0 . 0 0 5 units), or saline ( 0 . 9 # ) . Due to the small size of 
the livers, two or three livers from the same treatment group 
were pooled for assay. Fetuses injected on the nineteenth day 
of gestation were treated with the same hormones and the same 
dosages as those in the glycogen experiment. 
In this experiment, one horn within a female was treat­
ed with saline while the other horn was treated with one hor­
mone. Care was taken to assure alternation of the horn used 
for the controls from mother to mother. This design allowed 
comparison of a treatment group to its own set of controls. 
Following removal, the liver tissues were quickly fro­
zen in liquid nitrogen and stored frozen until assay. Each 
liver was assayed for the activities of the independent and 
dependent forms of UDPG-glycogen glucosyltransferase or for 
the activities of hexokinase and glucokinase. 
The Isolation and Quantitation of Glycogen 
Glycogen was determined by a modification of the method 
of Good, Somogyi, and Cramer ( 3 2 ) . Livers from 20 and 21 
day fetuses treated 24 hours previously with growth hormone, 
insulin, thyroxine, or saline were collected. Each liver 
was added to 1 , 5 ml. of JOfo KOH and then heated for twenty 
minutes in a boiling water bath. Glycogen was precipitated 
with 2 . 5 ml. of 9 5 $ ethanol overnight at room temperature. 
The precipitates were collected after centrifugation for 
1 4 
ten minutes at 2 5 0 0 x g , and washed three times by centrifuga-
tion using 3 ml. of 9 5 $ ethanol at each step. After the final 
wash, the precipitates were air dried, and the samples were 
frozen until assay. 
The glycogen samples were hydrolyzed in 2 ml. of 2 N 
H2SOZ1 for 2 nr. at 1 0 0 ° C , diluted to 5 ml. with distilled 
water, and 0 . 0 5 ml. of each glycogen sample was added to 4 
ml. of Crlytel Reagent (Pfizer). A reagent blank using 0 . 0 5 
ml. of distilled water and 4 glucose standards ( 5 0 mg. %9 100 
nig. fo9 2 0 0 mg. fo, 400 mg, %) were prepared similarly. The 
reagent blank, glucose standards, and experimental samples 
were placed in a boiling water bath for exactly 10 min., 
cooled to room temperature, and the absorbance read at 630 
nm. The glucose hydrolyzed from the glycogen reacts stoichi-
ometrically with the ortho-toluidine in the Glytel Reagent 
to yield a colored complex, 
A standard curve was prepared by plotting mg, % gly­
cogen of the standards versus their respective absorbances. 
The absorbances of the unknown could then be converted to mg. 
# glycogen by interpolating from this curve and correcting 
for dilution, 
UDPG-glycogen glucosyltransferase Assay 
UDPG-glycogen glucosyltransferase activity was deter­
mined by the method of Das and Hem with some modification ( 3 3 ) . 
The frozen tissue was homogenized with an ice-cold buffer 
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(pH 7 . 0 ) containing 10 mM ethylenediaminetetraacetic acid 
(EDTA), 50 mM KF, and 10 mM Tris(hydroxymethyl)aminomethane 
hydrochloride in a Potter-Elvehjem homogenizer. The ratio of 
tissue to buffer was one gram to six ml. The homogenate was 
centrifuged at 4 5 0 0 x g for 10 min. The UDPG-glycogen glucosyl-
transferase assay mixture contained 6 . 7 mM UDP-glucose-^C 
( 5 0 0 , 0 0 0 dpm/um.) (New England Nuclear), 10 mg./ml. of rabbit 
liver glycogen, and 50 mM Tris(hydroxymethyl)aminomethane hy­
drochloride (pH 7 . 8 ) . The tissue extract ( 0 . 0 5 ml.) was add­
ed to tubes containing 0 . 1 ml. of the assay mixture; incuba­
tion was carried out at 30°C. for fifteen minutes in the pres­
ence and absence of glucose-6-phosphate ( 1 0 mM). The reaction 
was stopped by the addition of 1 ml. of 6% trichloroacetic 
acid (TCA) containing 1 mg./ml. glycogen and 2 mg./ml. LiBr. 
Glycogen was precipitated by the addition of 2 volumes ( 2 . 3 
ml.) of 9 5 $ ethanol. The tubes were allowed to stand refrig­
erated overnight to assure complete precipitation. The pre­
cipitate was filtered through Gelman Metricel GA - 6 filters with 
a pore size of 0 . 4 5 ^m. and washed six times with 2 ml. of 
6 6 $ ethanol. The glycogen retained by the filter was hydro-
lyzed with 0 . 7 5 nil. of diazyme (amyloglucosidase, Sigma) in 
1 . 0 M sodium acetate buffer ( 0 . 1 mg./ml.) at pH 5 . 0 in liquid 
scintillation vials. Fourteen ml. of Handifluor was added to 
the vials along with 0 , 3 5 ml of 1 N HC1 to facilitate solu­
bilization of the buffer in the scintillant. Radioactivity 
was measured in a Beckman LS-100C liquid scintillation counter. 
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An efficiency curve was prepared by plotting the exter­
nal standardization ratios (ESR) against the percentage of 
efficiency of several matched radioactive samples to which 
had been added varying quantities of acetate buffer. The 
readings obtained from the scintillation counter were con­
verted from counts per minute (cpm) to disintegrations per 
minute (dpm) by use of the following formulat 
cpm - cpm 1 K 
unknown blank = dpm of UDP-glucose- 1 C 
efficiency incorporated 
The reaction mixture contained 2 . 0 5 x 1 0 " ^ ^m. UDPG/dpm, In 
all cases the aliquot assayed contained 0 . 0 0 8 g. of liver tis­
sue, and incubation was carried out for 15 minutes. The acti­
vity of UDPG-glycogen glucosyltransferase was calculated in 
the following wayi 
[(sample dpm x 2 , 0 5 x l O- 6 M,moles UDPG/dpm) * , 0 0 8 g,] ^ 1 5 min, = 
unoles UDPG incorporated/g, liver/minute 
Hexokinase and Glucokinase Assays 
The activities of hexokinase and glucokinase were deter­
mined by a modification of the method of Jamdar and Greengard 
( 2 1 ) , The liver tissue was homogenized in five volumes of 
cold 0,15 M KC1, The homogenate was centrifuged at l 4 5 , 0 0 0 x g 
for 3 0 minutes 1 the supernatant was assayed for glucokinase 
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and hexokinase. The supernatant ( 0 . 0 2 5 ml.) was added to 3 
ml. of an incubation medium containing a 50 mM triethanola-
mine, 5 mM EDTA, and 5 mM MgClg buffer, pH 7.6* 0 , 5 mM NADP* 
5 mM ATP* 0 . 2 units of glucose-6-phosphate dehydrogenase (Sig­
ma), and one of two concentrations of glucose, 100 mM or 0 . 5 
mM. The formation of reduced NADP was measured by the in­
crease in optical density at 3^0 nm, over a 10 min. incuba­
tion at 24°C. A Beckman DBG spectrophotometer was used to 
measure optical density, Hexokinase was determined from the 
difference between the rates of incubations with 0 , 5 mM glu­
cose in the presence and absence of ATP, Glucokinase was de­
termined from the difference in reaction rates between the 
incubation with 1 0 0 mM glucose and the incubation with 0 , 5 mM 
glucose. This method of determining glucokinase is valid be­
cause incubation with 100 mM glucose results in saturation of 
hexokinase (which has a lower K m than glucokinase). All en­
zyme activity beyond the hexokinase activity in this assay can 
be attributed to glucokinase. 
The rates in absorbance units/min. were converted to 
nm. of glucose phosphorylated/g, of liver/min. The extinction 
coefficient of NADP is 2 optical density units / i m. Each ali­
quot assayed contained 0 . 0 0 5 g. of liver tissue. The activi­
ties were calculated using the following formulas! 
reaction rate (units/min.) = X iimoles NADP reduced/. 0 0 5 g./min. 
2 
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» X pinoles glucose 
2 phosphorylated / ,005 g./rain. 
~ 100(X) wnoles glucose 
phosphorylated/g./min. 
Early experiments demonstrated that the hexokinase reaction 
rate was linear with time beyond ten minutes, indicating that 
rates measured over that time were indeed measurements of ini­
tial rates. 
Statistical Methods 
The data obtained from glycogen determinations were ana­
lyzed using Tukey's Honestly Significant Difference method ( 3 4 ) j 
probability values from day 20 and day 21 were combined accord­
ing to the method of R. A. Fisher to yield one probability ( 3 4 ) , 
The data concerning the effects of hormonal administra­
tion on enzyme activity were analyzed by means of a two-way 
analysis of variance using the Statistical Package for the 
Social Sciences. Where linear regression computations indi­
cated a high correlation between fetal weight and enzyme ac­
tivity, the analysis of variance included weight as a covari-
ant. 
The effect of hormone treatment on fetal weight was 
tested with one-way analysis of variance. The effect of hor­
mone administration on placental weight was analyzed using 




Glycogen determinations on fetal livers exposed to 
growth hormone, insulin, and thyroxine demonstrated a signi­
ficant increase in glycogen accumulation with thyroxine ad­
ministration as compared with saline administration (P^).01) 
(See Table 1). Subsequent experiments on the effects of thy­
roxine, growth hormone, and insulin on the activity of the 
independent form of UDPG-glycogen glueosyltransferase yielded 
no treatment effect on that enzyme at either day 16 or day 20. 
The three hormones also had no effect on the activity of the 
dependent form of glucosyltransferase (See Table 2). Fetal 
glucokinase activity was found to be nonexistent on both day 
l6 and day 20 (See Table 3 ) . Treatment with growth hormone 
was found to approximately double the hexokinase activity on 
days 16 and 20 (See Table 4 and Figures 1 and 2 ) . While in­
sulin-treated fetuses showed an upward trend in hepatic hexo­
kinase activity when compared to controls within the same 
mother, there was no significant difference between the means 
(See Figure 3 ) . Thyroxine administration produced no signifi­
cant effect oh hexokinase activity. 
Only in analyzing the effect of insulin administration 
on hexokinase activity on day 20 was there found to be a high 
20 
correlation between fetal weight and enzyme activity; hence, 
this was the only case in which weight was used as a covari-
ant in the statistical analysis. 
Thyroxine administration effected an increase in fetal 
weight on day 2 0 ; the difference between the control and 
treated fetal weights was significant (P^ ) . 0 3 ) (See Table 5 ) . 
No other treatments altered fetal weights. 
Differences between placental weights of the experimen­
tal and control groups were insignificant (See Table 6), 
Table 1. The Effects of Hormone Administration on Fetal Glycogen 
on Day 20 and Day 21. (mg. glycogen/g. liver) 
Saline Growth Hormone Insulin Thyroxine 
Day 20 3 3 . 3 ± 4 . 5 2 3 2 . 3 + 4.51 
(N = 7 ) (N = 1 5 ) 
3 9 . 9 + 3 . 6 3 5 0 . 4 ± 1 . 6 7 ' 
(N = 13 ) (N = 1 2 ) 
Day 2 1 1 5 7 . 5 ± 3 . 9 9 6 6 . 9 + 5 . 1 ^ 
(N = 27) (N = 1 3 ) 
6 9 . 2 + 4 . 6 9 70.2 + 4.73' 
(N = 12) (N = 13) 
L 
All data above is listed as mean + standard error of the mean. 
Significantly different from saline controls (P< 0 . 0 1 ) using the method of R. A. Fisher 
(34) to combine the probability values for both time periods (obtained using Tukeys 
Honestly Significant Difference method). 
Table 2. The Effect of Hormone Administration on Fetal 
UDPG-glycogen glueosyltransferase I and D. 
UM/g, of liver/min,) 
Growth Hormone Insulin Thyroxine 
I D I D I D 




. 0 5 2 + .018 
(N = 9) 
. 0 9 6 + . 0 2 6 
(N = 9) 
P < . 2 6 5 
. 0 3 2 + .011 
(N = 9) 
.040 + .019 
(N = 9) 
P 2 .999 
. 1 2 3 + .023 
(N = 10) 
. 1 2 1 + .040 
(N = 7) 
P £ .999 
. 0 4 5 + .015 
(N = 10) 
.042 + .023 
(N = 7) 
P > .999 
.082 + . 0 2 5 
(N = 12) 
.077 + .017 
(N * 14) 
P > .999 
,041 + ,014 
(N * 12) 
,051 + .015 
(N = 14) 
P > .999 




.011 + .002 
(N = 7) 
.014 + . 0 0 3 
(N = 6) 
P ^ .999 
.014 + . 0 0 7 
(N = 7) 
. 0 1 0 + . 0 0 5 
(N = 6) 
P> .999 
. 0 1 5 + . 0 0 5 
(N = 7) 
. 0 1 6 + . 0 0 5 
(N » 7 ) 
P ^ .999 
.022 + . 0 0 9 
(N = 7) 
. 0 2 3 + . 0 1 1 
(N = 7) 
P > .999 
.014 + . 0 0 3 
(N = 5) 
, 0 0 5 + . 0 0 1 
(N = 5) 
P> .999 
,017 + .008 
(N = 5) 
. 0 1 5 + . 0 0 7 
(N = 5) 
P > .999 
1 
All data above is listed as mean + standard error of the mean. 
2 
Analysis of variance. 
Table 3. The Effect of Hormone Administration on Fetal Glucokinase Activity 
(j, M/g. of liver/min.) 





.019 + .008 
(N = 9) 
. 0 3 2 + . 0 1 5 
(N = 1 0 ) 
.999 
043 + .024 
(N = 8) 
041 + .019 
(N = 9) 
P > .999 
.011 + , 0 0 5 
(N = 15) 
.019 + .014 
(N = 12) 
P > .999 




. 0 0 2 + . 0 0 2 
(N = 1 0 ) 
. 0 0 3 + . 0 0 2 
(N = 8) 
P > .999 
007 + . 0 0 7 
(N = 6) 
004 + .002 
(N = 7 ) 
P ^ .999 
.000 
(N = 5) 
.017 + .017 
(N"= 5) 
P ^ .999 
All data above is listed as mean + standard error of the mean. 
Analysis of variance. 
Table 4, The Effect of Hormone Administration on Fetal Hexokinase Activity. 
(uM/g. of liver/ min.) 
Growth Hormone Insulin Thyroxine 
Day 2 0 1 
Treatment .318 + .041 .258 + .045 .140 + .021 
(N = 9) (N = 8) (N = 1 5 ) 
Control . 1 6 3 + .029 .180 + . 0 3 8 .168 + . 0 3 2 
(N = 10) (N = 9) (N = 12) 
Statistics 2 P ^ .020 P £ .125 P ^ .999 
Day 1 6 1 
Treatment . 0 9 1 + . 0 3 3 . 0 6 1 + . 0 1 1 . 0 5 8 + .017 
(N = 1 0 ) (N = 6 ) (N = 5 ) 
Control . 0 2 6 + . 0 1 3 . 0 5 1 + . 0 2 1 .046 + .024 
(N = 8 ) (N = 7) (N = 5 ) 
Statistics 2 P < . 0 2 3 P ^ .999 P ~ .999 
1 
All data above is listed as mean + standard error of the mean. 




6 \ Q UU 
\— < > _l > 1— QL U • < X CL LU cn c/) O < X Z Q. 
• x o lu u m D _j 
en 
UJ _J o 
.30 
0 0 
— TREATMENT ACTIVITY 
• CONTROL ACTIVITY 
I 
13 21 2 3 2 4 3 3 
MOTHER NUMBER 
FIGURE I. T H E EFFECT O F GROWTH HORMONE ADMINISTRATION O N HEXOKINASE 
ACTIVITY AS COMPARED WITH SALINE ADMINISTRATION O N DAY 16 IN 











0 8 X 
,06 
0 4 




— TREATMENT ACTIVITY 
• CONTROL ACTIVITY 
\ Q >- LU H H-f-. < > _l 
u o < x Q. lu in if) o < x z Q. 
I—I 






. 10 i 
.00 
13 15 19 109 
MOTHER NUMBER 
FIGURE 2. T H E EFFECT OF GROWTH HORMONE ADMINISTRATION ON HEXOKINASE 
ACTIVITY A S COMPARED W I T H SALINE ADMINISTRATION ON DAY 20 IN 






















N . 5 0 




_1 .20 • 
. 10 
.00 
— TREATMENT ACTIVITY 
• CONTROL ACTIVITY 
1 
11 7F "T 19 
MOTHER NUMBER 
FIGURE 3. THE EFFECT O F INSULIN ADMINISTRATION O N HEXOKINASE 
ACTIVITY A S COMPARED W I T H SALINE ADMINISTRATION O N DAY 20 
IN FETUSES OF T H E SAME MOTHER. 
Table 5 . The Effect of Hormone Administration on Fetal weight. 
(grams) 
Growth Hormone Insulin Thyroxine 
Day 2 0 1 
Treatment 3 . 8 3 + .12 3 . 1 6 + . 0 9 3 . 7 9 ± .18 
(N = 9 ) (N = 10) (N = 12) 
Control 3 . 5 6 + .13 3 . 3 5 ± .17 3.20 + .18 
(N = 10) (N = 7 ) (N = 14) 
Statistics 2 P < ,l4l P < .274 P < . 0 3 0 
Day 1 6 1 
Treatment .47 + . 0 6 . 4? + . 0 5 .41 + .04 
(N " 10) (N = 7 ) (N = 5 ) 
Control .54 + .08 .42 + . 0 5 .41 + . 0 5 
(N s 8 ) (N = 7 ) (N = 5 ) 
Statistics 2 P < .506 P < .447 P < .982 
1 
All data above is listed as mean + standard error of the mean. 
2 Analysis of variance. 
Table 6 . The Effects of Hormone Administration on Placental Weights 
of Fetuses at Day 2 0 . 1 
Saline Growth Hormone Insulin Thyroxine 
Placental weight 2 0 . 6 0 5 + . 0 1 2 0 . 6 1 2 + .027 0 . 5 9 1 + . 0 1 5 0 . 5 9 9 ± . 0 1 5 
(grams) (N = " 4 9 ) (N = 2 7 ) (N = 3 0 ) (N = 2 7 ) 
1 
Treatment with Tukey»s Honestly Significant Difference method showed no significant 
differences between treatment groups and controls, 
2 




The majority of research data available on the effects 
of hormone administration in the fetus deals with the ef­
fects of glucocorticoids on glycogen metabolism and of thy­
roxine on some specific hormones of the late fetal and neo­
natal periods. A search of the literature yields a limited 
amount of reports on the effects of growth hormone or insulin 
administration in the fetus. Little is known about the effects 
of hormone administration on fetal metabolism; therefore, the 
available information on hormonal effects and mechanisms in 
the fetus is minimal. Because many aspects of fetal metabo­
lism differ from that seen in the adult, it cannot be assumed 
that the administration of a particular hormone will cause the 
same effects in the fetus as in the adult. Furthermore, dif­
ferences in hepatic competence in the fetus and in the adult 
make it difficult to assume that the effects of hormonal ad­
ministration are mediated through identical mechanisms. 
The Effects of Hormone Administration on Hepatic UDPC-
glycogen glucosyltransferase 
Hepatic glycogen determinations on fetuses treated 
with hormones indicated a significant effect of thyroxine on 
glycogen deposition ( P < 0 , 0 1 ) , These results served as an 
31 
impetus for testing the effect of thyroxine administration on 
UDPG-glycogen glucosyltransferase since this enzyme controls 
the deposition of fetal glycogen. The effects of growth hor­
mone and insulin administration were also tested because these 
hormones are known to produce glycogen deposition in the adult. 
UDPG-glycogen glucosyltransferase exists in two forms 
in liver ( 3 5 ) . The form which is active in the absence of 
glucose-6-phosphate is glueosyltransferase I (independent)\ 
the form active only in the presence of glucose*6-phosphate 
is glucosyltransferase D (dependent). It is generally be­
lieved that glucosyltransferase I is the physiologically ac­
tive form in heart, muscle, and liver tissue. The D form is 
considered to be physiologically inactive because of its low 
affinity (high K m ) for glucose-6-phosphate and because of in­
hibition by inorganic phosphate and adenosine triphosphate, 
Glucosyltransferase I is active because it has a high affinity 
for glucose-6-phosphate and lower K m for the substrate uridine 
diphosphoglucose ( 3 6 ) . 
It has already been noted that the earliest detection 
of UDPG-glycogen glucosyltransferase corresponds with the on­
set of insulin secretion on the twelfth day of gestation and 
that fetal glycogen deposition is enhanced by glucocorticoid 
administration. 
In these experiments, hormone administration resulted 
in no significant effect on the activity of either the I or 
32 
the D form of glucosyltransferase. The effect of thyroxine 
on glycogen deposition might be achieved by increased sub­
strate availability for the reaction. For example, thyroxine 
treatment in adults can elevate blood glucose levels thereby 
increasing incorporation into glycogen ( 3 7 ) . The effect in 
the fetus could be achieved by an increase in the permeabili­
ty of the hepatocyte to glucose or by an increase in activity 
of one or both of the two enzymes which catalyze the steps im­
mediately before the one catalyzed by glucosyltransferase in 
the glycogenic pathway. The result of an increase in either 
of these enzymes (phosphoglucomutase and UDPG pyrophosphoryl-
ase) would increase the availability of UDPG, 
Another possible explanation for the effect of thy­
roxine on glycogenesis involves alterations of cellular me­
tabolites other than glucose. Blatt et al. found that alter­
ing levels of metabolites (such as glucose-6-phosphate and 
adenosine triphosphate) can stimulate glycogen synthesis in 
the absence of glucosyltransferase activationi manipulation 
of intracellular metabolites can also regulate the activity 
of glucosyltransferase in the absence of hormonal influences 
( 3 8 ) . Under normal conditions changes in other metabolites 
or minerals (eg. magnesium, inorganic phosphate, nucleotides, 
sodium, potassium) may also serve a regulatory function. The 
administration of thyroxine is known to increase serum calci­
um levels and can accelerate active transport of sodium across 
isolated skin and bladder membranes (39» 40), Since the effect 
3 3 
of thyroxine on mineral metabolism in the hepatocyte may dif­
fer from that seen in the serum or in isolated membranes, fur­
ther experiments should be undertaken to identify the effect 
of thyroxine on those hepatic metabolites which can regulate 
the activity of this enzyme. Identification of those sub­
stances which affect the levels of these metabolites could 
provide more insight into the regulation of glycogenesis. 
The absence of a significant increase in glucosyltrans­
ferase activity with insulin treatment was surprising. Gril-
lo*s demonstration of the detection of glucosyltransferase 
concurrently with the onset of insulin secretion on the twelfth 
day of gestation indicated a possible interaction between the 
two. Since the effect of insulin on glucosyltransferase in 
the adult is mediated through the cyclic AMP system, the re­
sults obtained here may indicate lack of competence by the 
liver to respond to the hormone with cyclic AMP. 
The Effects of Hormone Administration on 
Hepatic Hexokinase 
The high activity of hexokinase before birth suggests 
a high capacity in liver for the phosphorylation of glucose. 
In the fetal liver, hexokinase is the rate-limiting enzyme in 
glycolysis (4l). Although little is known about its hormone 
sensitivity in the fetus, hexokinase activity is affected by 
hormone administration in the adult. Thyroxine and insulin 
both increase hexokinase activity (42). 
Since hexokinase activity is already high by the time 
3 4 
it is first measured (sixteenth day of gestation) in this ex­
periment, the objective of the research was not to find a 
hormonal trigger for this enzyme but to obtain information 
concerning the hormonal control of hexokinase in the fetus. 
Hexokinase exists as four isozymes in rat liver, which 
differ in kinetic properties and time of appearance. Isozyme 
A is the predominant isozyme in fetal rat liver with low lev­
els of isozymes B and C| these three isozymes have low K ms 
and reach their adult values by the time of weaning. At this 
time, the high-K m isozyme D (glucokinase) appears and reaches 
adult levels on the thirtieth postnatal day. While the amount 
of glucose intake seems to be a determinant of glucokinase ac­
tivity at the time of weaning, very little is known about the 
differentiation of the other isozymes ( 4 3 ) , 
It is known that 8 5 # of fetal hexokinase is in the 
form of isozyme A, The absence of glucokinase in the fetus 
is probably unimportant since control of fetal blood glucose 
concentration is maintained by the maternal liver. During 
early extrauterine life, the newborn rat can control its own 
carbohydrate metabolism without possessing hepatic gluookinase. 
Walker and Holland have attempted to imply that hepatic glu­
cokinase may be of limited importance in glucose utilization 
and acts primarily as an overflow mechanism to handle glucose 
phosphorylation when blood glucose concentration increases 
above normal ( 4 4 ) . Walker and Rao have emphasized that hepa­
tic glucokinase activities measured in vitro with 1 0 0 mM glucose 
3 5 
as the substrate are never likely to be achieved in vivo 
where blood glucose concentration in the hepatic portal vein 
rarely rises above 11 mM (45), This confined role of gluco­
kinase supports the concept that, under normal conditions, 
the role of the liver is to make glucose rather than to use 
it. 
The slow rate of development of glucokinase, the steady 
hexokinase activities during glucokinase development, and the 
effects of known inhibitors of protein synthesis suggest that 
the development of glucokinase results from an initiation of 
and an increasing ability to synthesize new protein (44). 
Starvation during the time when glucokinase activity should 
be increasing results in a decrease in the observed glucokinase 
activity. Subsequent glucose feeding results in a rapid in­
crease in glucokinase activity, indicating that the potential 
ability to synthesize glucokinase has increased despite the 
starvation. Thus, the presence of dietary glucose is not the 
only requirement for the development of glucokinase. Insulin 
can increase glucokinase activity primarily by its protein 
anabolic effect (45). Insulin may not only have an effect at 
the transcription level but also at the ribosomal level (46). 
Although the low K m hexokinases develop much earlier 
than glucokinase, perhaps the prenatal regulation of the four 
may be similar. Although no significant effect of insulin or 
thyroxine was seen on hepatic hexokinase activity, a distinct 
effect of growth hormone on both day 16 and day 20 was demon-
3 6 
strated ( P ^ 0 . 0 5 ) . Growth hormone promotes protein anabolism, 
and is known to be present in high plasma levels by day 19 of 
gestation (4?). Perhaps the almost doubled activity of hexo­
kinase in livers treated with growth hormone as compared to 
saline-treated fetal rats may be the partial result of this 
protein anabolic effect. Root suggested that human growth 
hormone may increase the ability of the ribosomes to attach 
to or to translate messenger ribonucleic acid (48). There is 
evidence in the adult that growth hormone stimulates amino 
acid transport across the cell membrane and into the cytoplasm 
of cells and that it stimulates amino acid incorporation into 
protein. This latter action of growth hormone is blocked by 
inhibitors of ribonucleic acid and protein synthesis (42). 
There is evidence that the activities of other fetal enzymes, 
such as glucose-6-phosphatase, may be increased by growth hor­
mone administration in the fetus (Porterfield, unpublished ob­
servations). Thus, the effect of growth hormone administration 
on hexokinase may be the result of a protein anabolic effect 
resulting in increased production of several enzymes in the 
fetus. If the protein anabolic effect of growth hormone were 
a nonspecific one, one would have expected glucosyltransferase 
to be increased by this hormone. However, this effect was not 
demonstrated by this researcher. 
In the adult, proteins made under the influence of 
growth hormone appear to increase the levels of cyclic AMP in 
cells (42)# which results in a decrease in the activity of 
3 7 
hexokinase. However, these experimental results showed an in­
creased hexokinase activity with growth hormone treatment, 
indicating perhaps that fetal liver on the nineteenth day of 
gestation may not possess the ability to produce adequate 
amounts of cyclic AMP in response to growth hormone or pro­
teins influenced by growth hormone. Since the competence of 
the liver to form cyclic AMP in response to growth hormone 
has not been adequately studied in the fetus, we cannot be 
sure that the mechanism for fetal response to growth hormone 
is identical to that seen in the adult; however, should the 
two mechanisms be similar, the inability of the liver to form 
cyclic AMP in this situation combined with the protein ana­
bolic effect seen with growth hormone could explain the noted 
increase in hexokinase activity. 
Even though the hexokinase activity found with insulin 
administration was not statistically different from the con­
trol values obtained, there appears to be a definite upward 
trend in several of the hexokinase activities of insulin-
treated fetal livers as compared to saline-treated livers with­
in the same mother (See Figure 4 ) , Use of a ranking statistic 
on the means of the treatment and control groups within mothers 
supported this bias, indicating a significant difference be­
tween the means (P ^ . 0 . 0 2 ) . Experiments with a greater number 
of animals are needed in order to confirm this result. 
Although thyroxine increases hexokinase activity in the 
adult, the same effect could not be demonstrated in the fetus. 
3 8 
Here, again, the liver may not possess the competence to re­
spond to thyroxine with the mechanisms required for increased 
hexokinase activity on the days tested. Injection of thyroxine 
later in gestation or addition of possible missing cofactors 
concomitant with thyroxine administration might lead to a re­
sponse in the fetus similar to that in the adult. 
The increase in fetal weight noted with thyroxine ad­
ministration might be associated with the protein anabolic ef­
fect of this hormone. This anabolic effect of thyroxine is 
achieved in the adult by an increase in the transfer of amino 
acids to the protein synthesizing site, thereby facilitating 




Thyroxine administration late in gestation results in 
increased glycogen deposition in fetal liver. However, thy­
roxine had no effect on the activity of either the I or the D 
form of fetal hepatic UDPG-glycogen glucosyltransferase on the 
sixteenth or the twentieth day of gestation. No effects on 
glucosyltransferase activity were obtained with growth hormone 
or insulin administration. 
The increase in glycogen deposition following thyroxine 
administration does not appear to be mediated through increased 
activity of glucosyltransferase. 
Glucokinase activity was found to be absent on the six­
teenth and the twentieth days of gestation as expected. 
Hexokinase activity was increased significantly at day 
1 6 and day 2 0 by the injection of growth hormone. This in­
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